Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11801311 | 0.88 | ADORA2A (0.31) | ADORA2AADORA1CDK1CCNB1CDK2 | |
| SCHEMBL6267281 | 0.86 | USP2 (0.30) | GDAALDH1A1 | |
| SCHEMBL7165315 | 0.83 | CDK1 (0.31) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL6692346 | 0.83 | BTK (0.31) | BTK | |
| SCHEMBL48130 | 0.81 | CYP1A2 (0.35) | GDA | |
| SCHEMBL67129 | 0.80 | CDK1 (0.31) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL17297733 | 0.80 | HPGD (0.33) | KDM4EALDH1A1KMT2A | |
| SCHEMBL22215309 | 0.80 | PDPK1 (0.33) | PDPK1 | |
| SCHEMBL4364337 | 0.80 | CDK1 (0.36) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL13269007 | 0.80 | HTR2C (0.37) | KDM4EALDH1A1GAAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240141360-A1 | MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNA | MONASH UNIVERSITY (AU) | 2024-05-02 | — | — | US | disclosed |
| CN-117916235-A | Cyclin dependent kinase inhibitors | 泰州亿腾景昂药业股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023187176-A1 | METHOD FOR DELIVERING A CARGO INTO CELL | Trince bv (BE) | 2023-10-05 | — | — | WO | disclosed |
| US-20230002790-A1 | POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPY | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20150297598-A1 | METHODS FOR TREATING RENAL DISEASE | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2015-10-22 | — | — | US | disclosed |
| US-20060004107-A1 | Method for designing a pharmaceutical compound specific to a desired receptor, a designed compound thereby, and pharmaceutical compositions containing the same | OJIMA MASANORI | 2006-01-05 | — | — | US | disclosed |
| US-4086347-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANTIEDEMIC AGENTS, HYPOTENSIVES | BOEHRINGER MANNHEIM GMBH (DT) | 1978-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004107-A1 | Method for designing a pharmaceutical compound specific to a desired receptor, a designed compound thereby, and pharmaceutical compositions containing the same | TBXA2R, PTAFR, PTGIR | ADORA2A 118/4885ADORA1 87/4885CDK1 2084/4885 |
| US-20150297598-A1 | METHODS FOR TREATING RENAL DISEASE | LDLR, APOL1, APOB | ADORA2A 1781/4885ADORA1 3004/4885CDK1 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.